Literature DB >> 20056798

WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults.

Animesh Pardanani, Ken-Hong Lim, Terra L Lasho, Christy M Finke, Rebecca F McClure, Chin-Yang Li, Ayalew Tefferi.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20056798     DOI： 10.1182/blood-2009-10-249979

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  21 in total

1.  Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis.

Authors:  Roberta Zanotti; Patrizia Bonadonna; Massimiliano Bonifacio; Anna Artuso; Donatella Schena; Maurizio Rossini; Omar Perbellini; Sabrina Colarossi; Marco Chilosi; Giovanni Pizzolo
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

2.  A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.

Authors:  Jason Gotlib; John H Baird; Tracy I George; Cheryl Langford; Isabel Reyes; Justin Abuel; Cecelia Perkins; Kurt Schroeder; Prithviraj Bose; Srdan Verstovsek
Journal:  Blood Adv       Date:  2019-08-13

3.  Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis.

Authors:  S Seitz; F Barvencik; T Koehne; M Priemel; P Pogoda; J Semler; H Minne; M Pfeiffer; J Zustin; K Püschel; C Eulenburg; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2013-02-23       Impact factor: 4.507

4.  Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT.

Authors:  Peter Valent; Sabine Cerny-Reiterer; Gregor Hoermann; Wolfgang R Sperr; Leonhard Müllauer; Christine Mannhalter; Hubert Pehamberger
Journal:  Am J Blood Res       Date:  2014-12-15

Review 5.  The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.

Authors:  Peter Valent; Joanna N G Oude Elberink; Aleksandra Gorska; Magdalena Lange; Roberta Zanotti; Björn van Anrooij; Massimiliano Bonifacio; Patrizia Bonadonna; Karoline V Gleixner; Emir Hadzijusufovic; Cecelia Perkins; Karin Hartmann; Anja Illerhaus; Serena Merante; Chiara Elena; Khalid Shoumariyeh; Nikolas von Bubnoff; Roberta Parente; Massimo Triggiani; Juliana Schwaab; Mohamad Jawhar; Francesca Caroppo; Anna Belloni Fortina; Knut Brockow; Rosemarie Greul; Akif Selim Yavuz; Michael Doubek; Mattias Mattsson; Hans Hagglund; Jens Panse; Vito Sabato; Elisabeth Aberer; Haifa Kathrin Al-Ali; Marie-Anne Morren; Judit Varkonyi; Alexander Zink; Marek Niedoszytko; Dietger Niederwieser; Luca Malcovati; Andreas Reiter; Vanessa Kennedy; Jason Gotlib; Olivier Lortholary; Olivier Hermine; Michel Arock; Hanneke Kluin-Nelemans; Wolfgang R Sperr
Journal:  J Allergy Clin Immunol Pract       Date:  2018-11-08

Review 6.  Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.

Authors:  John H Baird; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 7.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.

Authors:  Peter Valent; Cem Akin; Dean D Metcalfe
Journal:  Blood       Date:  2016-12-28       Impact factor: 22.113

Review 8.  Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.

Authors:  Alfonso Quintás-Cardama; Nitin Jain; Srdan Verstovsek
Journal:  Cancer       Date:  2011-06-20       Impact factor: 6.860

9.  Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM).

Authors:  Peter Valent; Elisabeth Aberer; Christine Beham-Schmid; Christina Fellinger; Wolfgang Fuchs; Karoline V Gleixner; Rosemarie Greul; Emir Hadzijusufovic; Gregor Hoermann; Wolfgang R Sperr; Friedrich Wimazal; Stefan Wöhrl; Brigitte Zahel; Hubert Pehamberger
Journal:  Am J Blood Res       Date:  2013-05-05

10.  Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.

Authors:  Peter Valent
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.